Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Corn could be key to saving your eyesight

NCT ID NCT02113254

Prevention Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether eating corn rich in zeaxanthin (a natural pigment) could increase the density of the macular pigment in the eye, which may help prevent age-related macular degeneration (AMD), a leading cause of blindness. Nine healthy volunteers aged 20-35 ate a daily serving of this corn for 10 weeks. The goal was to measure changes in macular pigment density and blood zeaxanthin levels.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
corn with high zeaxanthin content
What this could lead to
If it works, this could point toward a simple dietary strategy to help prevent age-related macular degeneration.
What could go wrong
This was a very small, early study with only 9 healthy volunteers, and it was terminated early. Results may not apply to older adults or those with the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

9 people

The number who actually took part.

Start date

Feb 2014

Finished

Jun 2014

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 35 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Healthy volunteers, men and women * Corrected visual acuity upper or equal to 8/10 in two eyes. * Age: 20 - 35 years * Free and written consent signed by the participant and the investigator before any examination required by the research * Subject agreeing to be registered in the national file * Affiliated subject of a national insurance scheme Exclusion criteria: * Presence of AMD signs on one or two eyes * Histories of other evolutionary ocular pathologies susceptible to complicate the evaluation of the AMD and of the visual acuity (glaucoma, high myopia forte (\>= - 6 dioptres), strong retinopathy…) * Subject operated of de cataract * Lens Opacities (NO\>=3, et/ou NC\>=3, et/ou C\>=1 et/ou P\>=1 according to the LOCSII method) * Food complements in the year wich precedes (list of complements in appendix 2) * Hypersensitive people in the tropicamide, in the atropine, its by-products, or in one of the excipients of the tropicamide * Patients at risk of angle closure glaucoma * Body Masse Index \>= 30 kg/m2 * Current smoking or stop for less than 12 months * Diabetes * High blood pressure * Hyperlipidemia * Neuro-inflammatory diseases * Chronical gastro-intestinal diseases (Crohn …) * Taking of continuous medicine during more than one month, during the last 12 months (exception of the contraceptive pill) * Pregnant or breast-feeding woman * Vegetarian Patient * Participation in another clinical trial during 30 days wich precedes * Not compliant subjects * Subject without french national insurance scheme * Subject under guardianship judicial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age macular degeneration are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Callosities age-related macular degeneration prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Age macular degeneration

Contacts and locations

Locations

  • CHU de Bordeaux

    Bordeaux, 33000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.